Compounded semaglutide and tirzepatide became available because millions of people needed these drugs and couldn't access or afford the brand-name versions. That access gap is real and the compounding market filled it. It also created a parallel system with different quality standards, a shifting legal status, and significant variation in what patients actually receive. Both things are true.
Why Compounding Exists in This Context
Ozempic and Wegovy experienced severe supply shortages beginning in 2022 as demand from both diabetes and weight management patients outpaced Novo Nordisk's manufacturing capacity. When the FDA places a medication on the official shortage list, it activates a legal provision allowing compounding pharmacies to produce copies of that drug for patients without adequate access to the approved version. Tirzepatide shortages followed as Mounjaro and Zepbound demand similarly outpaced supply.
The price gap created additional demand beyond shortage-related access. Brand-name Wegovy listed at 1,400 per month without insurance coverage; compounded semaglutide through telehealth platforms typically ran 300 per month. For the majority of patients whose insurance did not cover obesity medications — and most did not, for reasons rooted in how insurers calculate short-term cost-benefit — compounding represented the only financially viable path to treatment.
What Compounding Pharmacies Actually Make
Compounding pharmacies operate under two regulatory categories. 503A pharmacies are traditional compounding pharmacies that produce patient-specific preparations based on individual prescriptions. 503B outsourcing facilities are FDA-registered, operate under pharmaceutical-grade current Good Manufacturing Practice (cGMP) standards, and can produce drugs in larger quantities without patient-specific prescriptions.
Both categories can legally produce semaglutide base or tirzepatide base when an FDA shortage designation exists. The active peptide molecule is the same compound. What differs from pharmaceutical manufacturing is the rigor of purity testing, concentration accuracy verification, sterility controls, and batch-to-batch consistency. FDA does not test or pre-approve compounded products. Quality is entirely dependent on the individual pharmacy's internal practices.
Many compounding pharmacies and telehealth platforms added supplementary compounds to their formulations — most commonly vitamin B12, and sometimes NAD+ or other additives. These additions have no established clinical basis for weight management and exist primarily as a product differentiation strategy. They do not make the product safer or more effective.
Note(503A vs. 503B: the practical difference)
503B outsourcing facilities are held to higher manufacturing standards than 503A pharmacies and are subject to FDA facility inspections. If you are using a compounding pharmacy, a 503B facility is the meaningfully safer option. Ask directly which designation your pharmacy holds before ordering.
What the FDA Has Done
The FDA declared the semaglutide shortage resolved in early 2024. The tirzepatide shortage was similarly resolved in late 2024. When a shortage ends, the legal basis for compounding that specific drug expires — compounding pharmacies lose the shortage-derived authorization to produce copies.
Following the shortage resolutions, the FDA issued warning letters to compounding pharmacies and telehealth platforms that continued selling compounded semaglutide and tirzepatide. Enforcement has been uneven. As of mid-2026, compounded versions remain widely available through various telehealth platforms, though they operate in a legal gray zone that FDA has signaled it intends to close. The Pharmaceutical Research and Manufacturers of America and Novo Nordisk have both been active in pushing for stricter enforcement. Several large compounding telehealth platforms have received or anticipate receiving enforcement actions.
The legal status will likely continue shifting. Patients relying on compounded versions should be aware that access through their current platform is not guaranteed to remain stable.
Quality Concerns
Documented quality issues with compounded GLP-1s include incorrect concentration (both higher and lower than labeled), contamination, and sterility failures. The FDA's adverse event reporting database has received compounded GLP-1-related reports at rates that have drawn regulatory attention, though attributing specific adverse events to compounding-related quality failures versus expected pharmacological effects is not always straightforward.
This does not mean all compounded versions are dangerous or ineffective. Many patients have used compounded GLP-1s without incident. The problem is that quality control is variable and unverifiable by the patient at the time of use. A certificate of analysis from the pharmacy's own testing is not the same as independent third-party verification. Concentration inaccuracies are particularly consequential with peptides that have dose-dependent titration schedules — receiving a vial with twice the labeled concentration means patients self-administering what they believe is a 0.25 mg dose are actually receiving 0.5 mg, with corresponding effects on GI tolerability and potential adverse events.
Warning(What independent testing found)
Third-party testing of commercially available compounded semaglutide products has identified concentration errors in both directions and, in some cases, contamination with impurities. These findings are not universal across all compounders, but they underscore that the absence of FDA approval means the absence of independent quality verification. The patient has no way to know which category their product falls into.
How to Evaluate a Compounding Pharmacy
If you are using or considering compounded GLP-1s, the following criteria distinguish higher-quality providers from lower-quality ones:
Choose a 503B outsourcing facility over a 503A pharmacy. The manufacturing standards are meaningfully different. Ask directly which designation the pharmacy holds.
Request a certificate of analysis (CoA) from an independent third-party laboratory. A CoA from the compounding pharmacy's own testing confirms that someone ran a test, not that the test meets independent standards. Independent third-party CoAs are the meaningful document. Pharmacies that refuse to provide them or claim the information is proprietary are not worth using.
Be skeptical of B12 and additive marketing. "Semaglutide with B12" is a marketing differentiator with no established clinical rationale. Its prominence in a pharmacy's marketing materials correlates with prioritizing sales language over clinical accuracy.
Verify a real provider relationship. Some platforms issue prescriptions based entirely on online questionnaires, without a physician reviewing the patient's medical history, current medications, or relevant contraindications. This is a meaningful safety concern for a medication with real drug interactions, contraindications in patients with personal or family history of MEN2 or medullary thyroid carcinoma, and complex titration.
Check FDA warning letter databases. The FDA posts warning letters publicly. Searching the pharmacy or platform name will reveal whether it has received FDA enforcement action.
Insurance and Cost Alternatives
Several alternatives to compounding exist for patients who cannot afford brand-name pricing:
Novo Nordisk's patient assistance program (NovoCare) provides Wegovy and Ozempic at reduced or no cost for patients who meet income eligibility criteria, generally set at household income below 400% of the federal poverty level. Eli Lilly has an equivalent program for Mounjaro and Zepbound (Lilly Insulin Value Program and Lilly Cares).
Some insurance plans have expanded obesity medication coverage following increased clinical recognition of obesity as a chronic disease. Reviewing your specific plan's current formulary — not last year's — is worth doing, as coverage has been changing.
Telehealth platforms that provide brand-name prescriptions with manufacturer coupons represent a middle-ground option: higher cost than compounding, but pharmaceutical-grade product with documented quality controls.
User Sentiment
The compounding question divides GLP-1 communities sharply. People who couldn't afford brand-name therapy and had good results on compounded versions are vocal defenders. People who got inconsistent results — or who found their dose was off — are equally vocal about the risks. The middle ground is people who used compounding to access the drug, built habits and results, and then transitioned to brand-name once coverage improved.
Example(What the community says)
The most common arc: "I couldn't afford Wegovy. I used a compounded version for eight months, lost 30 pounds, and it clearly worked. When my insurance started covering Wegovy I switched and noticed the dosing felt more consistent." The failure cases tend to cluster around platforms that didn't require any real medical relationship — people who got generic questionnaire prescriptions, no titration guidance, and no follow-up when things went wrong.
Who It's For
Anyone who is currently using compounded GLP-1s, considering them, or helping a patient make this decision. The access problem is real — brand-name GLP-1 pricing puts these drugs out of reach for a large portion of the people who would benefit. This post isn't a case against compounding; it's a framework for doing it as safely as possible, and for knowing when the risk/benefit calculation tips the other way.
Summary(The short version)
Compounded semaglutide and tirzepatide became legal when FDA shortage designations created a window for compounding pharmacies to produce copies. Both shortage designations have ended, placing compounded versions in a legal gray zone the FDA has begun enforcing. Quality varies significantly — concentration errors and contamination have been documented in third-party testing. If you're using compounded GLP-1s, prefer a 503B outsourcing facility, request an independent third-party certificate of analysis, and avoid platforms marketing B12 additives or issuing prescriptions via questionnaire alone. The access problem is real; so are the quality risks. Patient assistance programs from Novo Nordisk and Eli Lilly remain underutilized options for income-eligible patients.